AU2007228574B2 - Inhibition of tumour growth - Google Patents
Inhibition of tumour growth Download PDFInfo
- Publication number
- AU2007228574B2 AU2007228574B2 AU2007228574A AU2007228574A AU2007228574B2 AU 2007228574 B2 AU2007228574 B2 AU 2007228574B2 AU 2007228574 A AU2007228574 A AU 2007228574A AU 2007228574 A AU2007228574 A AU 2007228574A AU 2007228574 B2 AU2007228574 B2 AU 2007228574B2
- Authority
- AU
- Australia
- Prior art keywords
- tumour
- cells
- lytic
- growth
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000004614 tumor growth Effects 0.000 title abstract description 10
- 230000005764 inhibitory process Effects 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 216
- 230000002101 lytic effect Effects 0.000 claims abstract description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000012010 growth Effects 0.000 claims description 29
- 230000009089 cytolysis Effects 0.000 claims description 25
- 230000028993 immune response Effects 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 7
- 239000000816 peptidomimetic Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000017066 negative regulation of growth Effects 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
- 230000004721 adaptive immunity Effects 0.000 abstract description 10
- 230000001939 inductive effect Effects 0.000 abstract description 9
- 238000002255 vaccination Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 38
- 102000004196 processed proteins & peptides Human genes 0.000 description 31
- 239000000427 antigen Substances 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 210000004881 tumor cell Anatomy 0.000 description 22
- 210000000987 immune system Anatomy 0.000 description 19
- 239000000370 acceptor Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000006054 immunological memory Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- SAUDSWFPPKSVMK-LBPRGKRZSA-N (2s)-2-(n-phenylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(O)=O)C1=CC=CC=C1 SAUDSWFPPKSVMK-LBPRGKRZSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JCZLABDVDPYLRZ-AWEZNQCLSA-N biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0605685.7 | 2006-03-21 | ||
| GBGB0605685.7A GB0605685D0 (en) | 2006-03-21 | 2006-03-21 | Inhibition of tumour growth |
| PCT/GB2007/000993 WO2007107748A2 (en) | 2006-03-21 | 2007-03-21 | Inhibition of tumour growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007228574A1 AU2007228574A1 (en) | 2007-09-27 |
| AU2007228574B2 true AU2007228574B2 (en) | 2013-06-20 |
Family
ID=36383910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007228574A Ceased AU2007228574B2 (en) | 2006-03-21 | 2007-03-21 | Inhibition of tumour growth |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2010204A2 (OSRAM) |
| JP (1) | JP2009530359A (OSRAM) |
| CN (1) | CN101466391A (OSRAM) |
| AU (1) | AU2007228574B2 (OSRAM) |
| CA (1) | CA2646589C (OSRAM) |
| GB (1) | GB0605685D0 (OSRAM) |
| NO (1) | NO20084053L (OSRAM) |
| WO (1) | WO2007107748A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821616D0 (en) * | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| GB201401877D0 (en) * | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| JP6813258B2 (ja) * | 2014-12-11 | 2021-01-13 | リティックス バイオファーマ エイエス | 化学療法の組み合わせ |
| JP6767096B2 (ja) | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| CA2976377A1 (en) * | 2015-02-12 | 2016-08-18 | The Johns Hopkins University | Inhibition of yap for breaking tumor immune tolerance |
| GB201601868D0 (en) | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| EP4637800A1 (en) | 2022-12-20 | 2025-10-29 | Lytix Biopharma AS | Compositions comprising an oncolytic peptide and chitosan |
| WO2024133580A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Medical products containing an aqueous formulation of a peptide |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890902B2 (en) * | 1998-08-28 | 2005-05-10 | Alpharma As | Cytotoxic modified lactoferrin peptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861478A (en) * | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
| DE3854476T2 (de) * | 1987-07-06 | 1996-04-04 | Univ Louisiana State | Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden. |
| US5773413A (en) * | 1993-06-04 | 1998-06-30 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasias, and lytic peptides therefor |
| IL113244A0 (en) * | 1994-04-08 | 1995-07-31 | Demeter Biotech Ltd | Method of combating mammalian neoplasia and lytic peptides therefor |
-
2006
- 2006-03-21 GB GBGB0605685.7A patent/GB0605685D0/en not_active Ceased
-
2007
- 2007-03-21 JP JP2009500919A patent/JP2009530359A/ja active Pending
- 2007-03-21 CN CNA2007800154351A patent/CN101466391A/zh active Pending
- 2007-03-21 WO PCT/GB2007/000993 patent/WO2007107748A2/en not_active Ceased
- 2007-03-21 AU AU2007228574A patent/AU2007228574B2/en not_active Ceased
- 2007-03-21 CA CA2646589A patent/CA2646589C/en not_active Expired - Fee Related
- 2007-03-21 EP EP07732085A patent/EP2010204A2/en not_active Withdrawn
-
2008
- 2008-09-24 NO NO20084053A patent/NO20084053L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890902B2 (en) * | 1998-08-28 | 2005-05-10 | Alpharma As | Cytotoxic modified lactoferrin peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007107748A3 (en) | 2007-12-06 |
| GB0605685D0 (en) | 2006-05-03 |
| JP2009530359A (ja) | 2009-08-27 |
| AU2007228574A1 (en) | 2007-09-27 |
| NO20084053L (no) | 2008-11-28 |
| EP2010204A2 (en) | 2009-01-07 |
| WO2007107748A2 (en) | 2007-09-27 |
| CA2646589C (en) | 2016-05-03 |
| CA2646589A1 (en) | 2007-09-27 |
| CN101466391A (zh) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007228574B2 (en) | Inhibition of tumour growth | |
| ES2819282T3 (es) | Combinaciones de inhibidores de puntos de control inmunitarios | |
| HUT74425A (en) | A method for sensitization of cancer for killer cell mediated lysis | |
| US20250002854A1 (en) | Methods of generating populations of tumour-infiltrating t cells | |
| EP1712238A1 (en) | Anthracyclin induced immunogenic dead or dying cells composition | |
| US9109048B2 (en) | Inhibition of tumor growth | |
| WO2016091490A1 (en) | Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics | |
| WO2016071431A9 (en) | A combination for cancer therapy | |
| CA3221194A1 (en) | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) | |
| US11123398B2 (en) | Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics | |
| Orsolic | Possible molecular targets of bee venom in the treatment of cancer: application and perspectives | |
| Fidler | Therapy of disseminated melanoma by liposome‐activated macrophages | |
| JP7522770B2 (ja) | 術後補助療法剤 | |
| EP4420677A1 (en) | Vaccines against tert-positive tumors | |
| JPS61502123A (ja) | 抗腫瘍活性を有する薬剤学的生成物；抗腫瘍療法への薬剤学的生成物または薬剤学的組成物の使用 | |
| WO2012102753A2 (en) | Metalloproteinase oligopeptides and their therapeutic use | |
| CN103974968A (zh) | 免疫调节剂金属肽(immp)和包含其的组合物 | |
| Zhou et al. | Blocking Blood Supply to Breast Carcinoma With a DNA Vaccine Encoding VEGF Receptor-2 | |
| Kim et al. | High Efficacy of | |
| BRPI0904468A2 (pt) | imunoterÁpico, composiÇço farmacÊutica e uso de imunoterÁpico para manufatura de medicamento para uso no tratamento de cÂncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |